Regression of oral hairy leukoplakia after orally administered acyclovir therapy.
To define the role of Epstein-Barr virus (EBV) in the pathogenesis of oral hairy leukoplakia, 13 human immunodeficiency virus-seropositive men with clinical and histologic evidence of oral hairy leukoplakia were enrolled in an open-label trial of orally administered acyclovir therapy (3.2 g/d for 20 days). Of six patients who received therapy, five exhibited clinical regression. Once therapy was discontinued, recurrences occurred in all responders. Among seven patients who refused therapy, no spontaneous remissions occurred. Before therapy, EBV replication within the leukoplakia was demonstrated by immunofluorescence tissue staining or electron microscopy in five patients who were studied. Human papillomavirus was not detected by immunocytochemistry or electron microscopy from tissue specimens of six patients. After therapy, biopsy specimens from two patients with complete responses revealed a normalization of histologic abnormalities and an inability to detect EBV in previously involved mucosa by immunofluorescence or in situ DNA hybridization assays. It was concluded that EBV replication within the epithelial cells of the tongue is necessary for the development of oral hairy leukoplakia.
Resnick
L
L
Department of Dermatology, Mount Sinai Medical Center, Miami Beach, FL 33140.
Herbst
J S
JS
Ablashi
D V
DV
Atherton
S
S
Frank
B
B
Rosen
L
L
Horwitz
S N
SN
D000212:Acyclovir / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D002176:Candida albicans / Q000302:isolation & purification; D006679:HIV Seropositivity / Q000150:complications; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007972:Leukoplakia, Oral / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D000212:Acyclovir